Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aluminium Hydroxide→

Aluminium Hydroxide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
21645-51-2
Molecular formula
AlH3O3
Molecular weight
78.004 g/mol
Drug class
Inorganic antacid and phosphate-binding agent
Mechanism of action
Neutralises gastric hydrochloric acid to reduce gastric acidity. In the gastrointestinal tract it also binds dietary phosphate to form poorly absorbed aluminium-phosphate complexes, reducing phosphate absorption.
Indications / reported uses
  • Symptomatic relief of acid-related dyspepsia, heartburn and gastro-oesophageal reflux in authorised antacid formulations
  • Control of hyperphosphataemia in selected patients with chronic kidney disease using product-specific phosphate-binding regimens

Sources: US DailyMed — Aluminium hydroxide antacid products · NLM MeSH — Aluminium hydroxide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aluminium Hydroxide Environmental Risk Assessment (ERA) (the Aluminium Hydroxide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.